Dapiglutide (formerly ZP 7570) is a dual GLP-1 and GLP-2 receptor agonist developed by Zealand Pharma.[1][2]

Dapiglutide
Clinical data
Other namesZP 7570
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII
Chemical and physical data
FormulaC192H302N46O57
Molar mass4166.793 g·mol−1

References

edit
  1. ^ Reiner, Johannes; Berlin, Peggy; et al. (July 2022). "Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel". Journal of Parenteral and Enteral Nutrition. 46 (5): 1107–1118. doi:10.1002/jpen.2286. PMID 34705281.
  2. ^ Olsen, Minna B.; HöVelmann, Ulrike; et al. (1 June 2022). "335-OR: Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects". Diabetes. 71 (Supplement_1). doi:10.2337/db22-335-OR. S2CID 249256542.